不同剂量重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎的临床对比分析

Clinical comparison of different doses of recombinant human interferon 1B aerosolized treatment of bronchiolitis in children

目的:研讨用不同剂量的重组人干扰素α1b对毛细支气管炎患儿进行雾化吸入治疗的临床效果。方法:选取自贡市妇幼保健院2017年12月至2019年6月收治的157例毛细支气管炎患儿作为研究对象。根据治疗方案的不同将其分为大剂量组(53例)、小剂量组(53例)和常规组(51例)。对三组患儿均进行常规治疗。在此基础上,为大剂量组患儿采用大剂量重组人干扰素α1b进行治疗,为小剂量组患儿采用小剂量的重组人干扰素α1b进行治疗。然后对比三组患儿的临床疗效、临床症状及体征消失的时间、WBC、RBC、PLT和不良反应的发生率。结果:与常规组患儿相比,大剂量组患儿和小剂量组患儿治疗的总有效率均较高,P<0.05。大剂量组患儿与小剂量组患儿治疗的总有效率相比,P>0.05。治疗后,大剂量组患儿和小剂量组患儿住院的时间、退热的时间、喘息症状缓解的时间、肺部啰音消失的时间和三凹征改善的时间均短于常规组患儿,P<0.05;大剂量组患儿住院的时间、退热的时间、喘息症状缓解的时间、肺部啰音消失的时间和三凹征改善的时间均短于小剂量组患儿,P<0.05。三组患儿治疗前后的WBC、RBC和PLT、不良反应的发生率相比,P>0.05。结论:用大剂量的重组人干扰素α1b和小剂量的重组人干扰素α1b对毛细支气管炎患儿进行雾化吸入治疗的效果均较好。与采用小剂量的重组人干扰素α1b相比,用大剂量的重组人干扰素α1b对毛细支气管炎患儿进行雾化吸入治疗可更快地改善其临床症状及体征,且安全性较高。

Objective:To investigate the clinical effect of different doses of recombinant human interferon 1B in the treatment of children with bronchiolitis by atomization inhalation.Methods:157 children with bronchiolitis admitted to Zigong Maternal and Child Health Hospital from December 2017 to June 2019 were selected as study subjects.They were divided into high-dose group(53 cases),low-dose group(53 cases)and conventional group(51 cases)according to different treatment regiments.All children in the three groups received routine treatment.On this basis,the children in the high-dose group were treated with high-dose recombinant human interferon 1B,and the children in the low-dose group were treated with low-dose recombinant human interferon 1B.Then,the clinical efficacy,the disappearance time of clinical symptoms and signs,WBC,RBC,PLT and the incidence of adverse reactions were compared among the three groups.Results:Compared with the conventional group,the total effective rate was higher in the high-dose group and the low-dose group(P<0.05).The total effective rate of the high-dose group was P>0.05 compared with that of the low-dose group.After treatment,the time of hospitalization,the time of antipyretic,the time of relief of wheezing symptoms,the time of disappearance of rhonchus in the lungs and the time of improvement of tripitus in the high-dose group and the low-dose group were shorter than those in the conventional group(P<0.05).The time of hospitalization,time of antipyretic,time of relief of wheezing symptoms,time of disappearance of rhonchus in the lungs and time of improvement of trident were shorter in the high-dose group than in the low-dose group(P<0.05).The incidence of WBC,RBC,PLT and adverse reactions in the three groups before and after treatment was compared,and P>0.05.Conclusion:High dose of recombinant human interferon 1B and low dose of recombinant human interferon 1B are effective in the treatment of children with bronchiolitis.Compared with the use of small doses of recombinant human interferon alpha 1B,the treatment with high doses of recombinant human interferon alpha 1B improves the cli nical symptoms and signs of bronchiolitis children more rapidly and with higher safety.